Day: November 20, 2020

4730-54-5,4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a solution of 1,4,7-triazacyclononane (2 mmol) in distilled ethanol (50 mL) containing molecular sieve was added 1 equiv of aldehyde. The reaction mixture was stirred at room temperature. The solution was filtered and the filtrate was evaporated under reduced pressure to yield the aminal adduct.

As the paragraph descriping shows that 4730-54-5 is playing an increasingly important role.

Reference£º
Article; Roger, Melissa; Patinec, Veronique; Bourgeois, Martine; Tripier, Raphael; Triki, Smail; Handel, Henri; Tetrahedron; vol. 68; 27-28; (2012); p. 5637 – 5643;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.29176-55-4,2,9-Dichloro-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: Diaryl-substituted phenanthrolines were prepared by combining thedihalo-substituted phenanthroline with the appropriate phenylboronicacid in a 100 mL Schlenk flask. The solids were suspended in 30 mL oftoluene and 20 mL of 2 M Na2CO3(aq), then purged with Ar for 15 min.Subsequently, Pd(PPh3)4 (0.175 g, 0.15 mmol) was added to the flask,purged for an additional 15 min, then heated at reflux under Ar whilerapidly stirring. After 48 h, the biphasic mixture was cooled to roomtemperature and the two layers were isolated. The aqueous layer waswashed with dichloromethane and all organic fractions were combined,dried using anhydrous MgSO4, and filtered. The solvent was removedby rotary evaporation, and the solids were recrystallized with minimaltoluene followed by vacuum filtration. If necessary, the volume of theresulting filtrate was reduced and hexanes added to induce precipitation.The mixture was vacuum filtered and resulting white solids were collected., 29176-55-4

As the paragraph descriping shows that 29176-55-4 is playing an increasingly important role.

Reference£º
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

(e) Synthesis of BRI7160 and BRI7161; The compounds were prepared according to Reaction Scheme 4: Compound 4 was prepared following the method of R. Guilard et al., Bull. Soc. Chim. Fr., 1996, 133, 65-73.A magnetically stirred suspension of compound 4 (430 mg, 0.86 mmol), (4-bromomethyl) methyl benzoate (217 mg, 0.95 mmol), KHCO3 (172 mg) and K2CO3 (174 mg) in dry acetonitrile (17 ml) was heated at reflux for 18 h under an atmosphere of nitrogen. The reaction mixture was cooled to room temperature then concentrated under reduced pressure to yield a straw coloured oil which was purified by flash chromatography (silica, 5% methanol/dichloromethane elution). Concentration of the appropriate fractions (RF 0.38) afforded adduct 5a as a clear, colourless oil. Mass Spectrum (APCI) m/z 649 [(M+H)+, 100%]., 170161-27-0

As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Patent; Prana Biotechnology Ltd; US7704987; (2010); B1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.17217-57-1,4,4′-Dimethoxy-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

General procedure: The synthesis of complexes was carried out by single potsynthesis. An anhydrous methanolic solution (10 mL) of 4-fluoro-N-salicylideneaniline (0.6456, 3 mmol) was addeddropwise to a vigorously stirred solution of 2,2?-bipyridine(0.1561, 1 mmol) in 10 mL methanol. To this solution ofligands, a methanolic solution of EuCl3 (0.2583 g, 1 mmol)was added slowly with continuous stirring. The pH of thereaction mixture obtained was adjusted to 6.0?7.0. Afteradjusting the pH, the reaction mixture was refluxed at 60 ¡ãC.The refluxing was continued for 5 h. The light yellow solutionso obtained was evaporated at room temperature to give thesolid compound which was extracted with diethyl ether. Thecompound obtained after extraction is C1 (Scheme 1).

17217-57-1, 17217-57-1 4,4′-Dimethoxy-2,2′-bipyridine 2733927, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Sengar, Manju; Narula, Anudeep Kumar; Journal of Fluorescence; vol. 29; 1; (2019); p. 111 – 120;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4199-88-6,5-Nitro-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: A 0.5 mmol quantity of copper(II) nitrate trihydrate was treated with 1.0 mmol of phen (or nphen) in ethanol (20 ml) under stirring conditions for 0.5 h. The product was isolated, washed with ethanol and set aside for crystallization by slow evaporation at room temperature. Green crystals were crystallized from the solution after a week. The structure of [Cu(phen)2(H2O)](NO3)2 has been previously determined by Nakai and Deguchi [43], by Catalan et al. [44], by Szpakolski et al. [45], by Zhou [46] and by Boutebdja et al. [47]. Complex 1: Yield was 87%. Anal. Calcd. for C24 H18 Cu N8 O12 (673.99 g mol-1) (%): C, 43.18; H, 2.67; N,16.63. Found: C, 42.77; H, 2.69; N, 16.63.

4199-88-6, The synthetic route of 4199-88-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Inci, Duygu; Aydin, Rahmiye; Vatan, Oezguer; Yilmaz, Dilek; Genckal, Hasene Mutlu; Zorlu, Yunus; Cava?, Tolga; Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy; vol. 145; (2015); p. 313 – 324;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

787-70-2, [1,1′-Biphenyl]-4,4′-dicarboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,787-70-2

Manganese(II) chloride (0.075 mmol, 10 mg), dipyridylacetylene(0.075 mmol, 14 mg) and biphenyl-4,4?-dicarboxylic acid (0.075 mmol, 18 mg) were suspendedin a mixture of dimethylformamide (8 mL), water (1 mL)and ethanol (1 mL) in a glass autoclave. The closed vesselwas then heated at 110 C over a period of 3 days. Then,the mixture was allowed to cool to rt in a rate of 5 C h-1,whereupon long needles formed which were filtered offand subjected to single crystal X-ray diffraction. Yield:14 mg (58%); dec. < 379 C. As the paragraph descriping shows that 787-70-2 is playing an increasingly important role. Reference£º
Article; Smeyanov, Alexey; Nieger, Martin; Gustus, Rene; Maus-Friedrichs, Wolfgang; Schmidt, Andreas; Zeitschrift fur Naturforschung, B: Chemical Sciences; vol. 70; 12; (2015); p. 897 – 902;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

Compound 43 (50 mg, 0.063 mmol) and (3-bromopropyl)- trimethylammonium bromide (164mg, 0.63 mmol, LOEQV.) are dissolved and potassium carbonate (130 mg, 0.95 mmol, 15 eqv. ) is suspended under argon in absolute DMF (30 ML) and the mixture is stirred at 55C for 12 h. The solvent is removed in vacuo at 50C and the residue applied to a pad (2 cm deep) of silica. The unreacted ammonium salts are washed off with methanol (lOOOmL) and the product is eluted with acetic acid: methanol: water (3: 2: 1 by vol. ). The solvent is removed under reduced pressure and the residue further purified by chromatography on a column (100G) of Sephadex LH-20 using n-butanol: water: acetic acid (4: 5: 1 by vol. , upper phase) as the eluent. The solvents are removed under reduced pressure and the residue dissolved in methanol and passed through a small column of anion exchange resin (Amberlite IRA 400, chloride form) using methanol as eluent. After evaporation of solvent, the crude product is dissolved in the minimum amount of methanol and diethylether (50 mL) added. The solution is centrifuged for 15 min. The supernatant liquid is evaporated to dryness and the residue dried at high vacuum to give the product as a violet solid. 1H-NMR : 5H (300MHZ, CD30D) : 0.90 (t, 3H, 3J= 7.5 Hz), 1.25-1. 41 (m, 8H), 1.45 (bs, 2H), 1.87 (bs, 2H), 2.38 (bs, 6H), 3,29 (bs, 27H), 3.67 (t, 6H, 3J= 7. 5 Hz), 4.01 (t, 2H, 3J= 7. 5 Hz), 4.30 (t, 6H, 3J= 7.5 Hz), 7.11 (d, 2H, 3J= 7.5 Hz), 7. 38 (d, 6H, 3J= 7.5 Hz), 7.95 (d, 2H, 3J= 7.5 Hz), 8.11 (d, 6H, 3J= 7. 5 Hz), 8.93 (bs, 8H)

3779-42-8, 3779-42-8 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide 151145, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33454-82-9,Lithium trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.

General procedure: N-alkylated product of di/trimeric imidazolium bromide (1.0 equi.)is treated with NaBF4/KPF6/LiCF3SO3 (3.05 equi.) in the presence of10 mL of deionized water at room temperature with stirring for about1 h afforded the anion exchanged product of di/trimeric imidazoliumcation with different anions. After the anion exchanged reaction,Soxhlet extractions is done to removemetallic bromide fromdi/trimericimidazolium salts using 100 mL of dry THF for about 1 h reflux to giverespective imidazolium salt in quantitative yield, 33454-82-9

The synthetic route of 33454-82-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Ganapathi, Pandurangan; Ganesan, Kilivelu; Journal of Molecular Liquids; vol. 233; (2017); p. 452 – 464;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.49669-22-9,6,6′-Dibromo-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

A mixture of 2-borylpyrrole*) (1.33 g, 4.14 mmol), 6,6′-dibromo-2,2′-bipyridine (500 mg, 1.59 mmol), Pd(OAc)2 (7.4 mg, 0.033 mmol), PPh3 (17.3 mg, 0.066 mmol), and K2CO3 (885 mg, 6.40 mmol) was stirred in DMF-H2O (16-4 ml) at 90 C under argon for 24 h. After cooling under argon, water (20 ml) was added to cause precipitation. The filtered precipitate was recrystallized from CH2Cl2-MeOH to give gray powder of the product. (* Setsune, J.; Toda, M.; Watanabe, K.; Panda, P. K.; Yoshida, T. Tetrahedron Lett., 2006, 47, 7541.)6,6′-bis(5-carboethoxy-3,4-diethyl-2-pyrryl)-2,2′-bipyridine: Yield 89%. Mp 193C. 1H NMR (400 MHz, d-value, in CDCl3) 9.97 (br, 2H, NH); 8.37, 7.63 (d’2, 2H’2, J = 8.0 Hz, pyridine-b-H); 7.90 (t, 2H, J = 8.0 Hz, pyridine-g-H); 4.40 (q, 4H, J = 7.1 Hz, OCH2Me), 2.82, 2.82 (q’2, 4H’2, J = 7.0 Hz, CH2Me); 1.42 (t, 6H, J = 7.0 Hz, OCH2Me), 1.28, 1.21 (t’2, 6H’2, J = 7.6 and 7.4 Hz, CH2Me). ESI-MS 543.274/543.297 (found/calcd for C32H38N4O4+H+). Analysis calcd. for C32H38N4O4?H2O: C, 68.55; H, 7.19; N, 9.99. Found: C, 68.05; H, 6.91; N, 9.92., 49669-22-9

As the paragraph descriping shows that 49669-22-9 is playing an increasingly important role.

Reference£º
Article; Setsune, Jun-Ichiro; Kawama, Miku; Nishinaka, Takeshi; Tetrahedron Letters; vol. 52; 15; (2011); p. 1773 – 1777;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The modification of CD and the subsequent later hydroxylationwere performed as reported in our previous works [26,27]. Briefly,an ice-cooled solution of CD in THF containing TEA was added drop-wise to the TMCS. The reaction mixture was stirred for 20 h at roomtemperature and then for 2 h at 60C. The product was extractedwith chloroform and washed with water. The obtained productwas hydrosilated with the Pt(COD)Cl2catalyst precursor and TMS(TMS/catalyst = 120 mol ratio) at 40C, using toluene as the sol-vent. The reaction mixture was stirred for 5 h at 90C under a N2atmosphere. Purification was performed by flash chromatography(hexane-acetone-TEA = 40:18:1).

485-71-2, 485-71-2 Cinchonidine 101744, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Campos, Cristian H.; Torres, Cecilia C.; Osorio-Vargas, Paula; Mella, Claudio; Belmar, Julio; Ruiz, Doris; Fierro, Jose L.G.; Reyes, Patricio; Journal of Molecular Catalysis A: Chemical; vol. 398; (2015); p. 190 – 202;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI